 NEW YORK, April 19, 2021 GLOBE NEWSWIRE -- Protara Therapeutics, Inc. Nasdaq: TARA, a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 120,000 shares of common stock to Martín Sebastian Olivo, M.D., Protaras newly appointed Chief Medical Officer. 